Clinical trials: Liver Tumour
Liver Transplantation, Hepatocellular Carcinoma
Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma
As key biomarkers in HCC, AFP and PIVKA-II reflects biological features of tumor and has been widely applied for clinical diagnosis.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist-II
- Trial name
- NCT06331260
- Volunteers
- 600 people
- Sponsor
- Zhejiang University
Carcinoma, Hepatocellular
Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma
The aim of this study is to compare the efficacy of sorafenib to 5-fluorouracil/mitomycin in HCC patients with pulmonary metastasis whose intrahepatic tumors has been controlled with locoregional therapies.
- Trial name
- NCT01171482
- Testing
- 5-FU, Mitomycin, sorafenib
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Seoul National University Hospital
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Hepatocellular Carcinoma
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC.
- Trial name
- NCT03519997
- Testing
- Pembrolizumab, Bavituximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- David Hsieh
Chronic Liver Disease, Hepatocellular Carcinoma
Genetic Polymorphisms of TNF-α Promoter and HBV Genotype on Outcome of HBV-Related Chronic Liver Disease
The prognosis of Hepatitis B virus (HBV)infection varies from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma (HCC).Both viral and host genetic factors contribute to disease severity.
- Trial name
- NCT00629668
- Testing
- TNF-alpha and HBV genotype, TNF-alpha and HBV genotypes
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Unresectable Hepatocellular Carcinoma
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma
- Trial name
- NCT05660213
- Testing
- Targeted drugs combined with anti-PD-1/PD-L1 antibodies, TACE (transarterial chemoembolization) combined with targeted/immunotherapy, Lenvatinib monotherapy
- Volunteers
- 750 people
- Sponsor
- Fudan University
Pancreaticoduodenectomy, Pancreatectomy
Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.
The purpose of this study is to demonstrate the safety and benefit of auto-transfusion filtered blood in patients undergoing major surgical oncology procedures.
- Conditions
- Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy
- Trial name
- Cellsaver (NCT00708513)
- Where
- 2 sites in United States
- Volunteers
- 98 people
- Sponsor
- University of Louisville
Carcinoma, Hepatocellular
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
- Trial name
- NCT00987935
- Testing
- Sorafenib, BIBF 1120
- Where
- 16 sites in South Korea, Taiwan
- Volunteers
- 134 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Chronic Kidney Diseases
Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY)
This research programme seeks to combine the resources of NHS primary care, with the leading spectroscopic work in low-magnetic fields of the Wilson Group (Nottingham Trent University) to demonstrate the potential for benchtop…
- Conditions
- Diabetes, Chronic Kidney Diseases, Cancer, Bowel Disease
- Trial name
- BRANCH-P (NCT05473325)
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Willows Health
Neuroectodermal Tumors, Primitive, Liver Neoplasms
NAC to Prevent Cisplatin-induced Hearing Loss
Cisplatin is a key chemotherapy agent for the treatment of multiple childhood cancers but causes permanent hearing loss. This study investigates the drug N-acetylcysteine (NAC) to determine the dose necessary to protect hearing…
- Conditions
- Neuroectodermal Tumors, Primitive, Liver Neoplasms, Osteosarcoma, Other Childhood Cancers Using Cisplatin-based Regimens
- Trial name
- NCT02094625
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's Hospital Los Angeles
Carcinoma, Hepatocellular
Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China
This study is to obtain the characteristics and treatment pattern of the unresectable HCC patients who are candidates for systemic therapy and in whom a decision to treat with sorafenib from early stage of TACE treatment course…
- Trial name
- SUCCESS (NCT01839630)
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- China
- Volunteers
- 302 people
- Sponsor
- Bayer
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07558200
- Testing
- Intervention1：FXB0871, Intervention2：FXB0871, Intervention3：FXB0871
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Hepatocellular Carcinoma (HCC), Liver Ablation
International Study on Treatment of Liver (HCC) Patients With IRE
Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation
- Conditions
- Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult
- Trial name
- LIVERHCC-IRE (NCT07192731)
- Testing
- Irreversible Electroporation
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Angiodynamics, Inc.
Hepatocellular Carcinoma, Chemoembolization, Therapeutic
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
The primary objective of this trial is to evaluate the sensitivity and specificity of 2D and 4D contrast enhanced ultrasound for monitoring transarterial chemoembolization (TACE) response 1-2 weeks and 1 month post treatment as…
- Trial name
- NCT02764801
- Testing
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- Where
- 3 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Refractory Hepatocellular Carcinoma
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Penpulimab in patients with hepatocellular carcinoma after standard treatment failure.
- Trial name
- NCT07075419
- Testing
- JDB153, Penpulimab
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Gastrointestinal Cancer
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
The study goal is to compare surgeon-palliative care team co-management, versus surgeon alone management, of patients and family members preparing for major upper gastrointestinal cancer surgery.
- Trial name
- PERIOP-PC (NCT03611309)
- Testing
- Surgeon-palliative care team co management, Surgeon team alone management
- Where
- 5 sites in United States
- Volunteers
- 379 people
- Sponsor
- Stanford University
Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)
Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors
Precision medicine is a major goal in oncology. It aims to tailor treatments to the specific characteristics of each patient's tumor.
- Trial name
- ELMIRA (NCT07178587)
- Testing
- Single tracer PET/CT, Multiplexed PET-CT
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Nantes University Hospital
Hepatocellular Carcinoma
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
The purpose of the study is to determine whether 4SC-201 alone or in combination with Sorafenib is effective and safe in the treatment of hepatocellular carcinoma in patients refractory to Sorafenib monotherapy.
- Trial name
- Shelter (NCT00943449)
- Testing
- 4SC-201, Sorafenib
- Where
- 15 sites in Germany, Italy
- Volunteers
- 57 people
- Sponsor
- 4SC AG
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.